Multicenter Evaluation of Ceftolozane/Tazobactam for Serious Infections Caused by Carbapenem-Resistant Pseudomonas aeruginosa

Jose M. Munita; Samuel L. Aitken; William R. Miller; Federico Perez; Rossana Rosa; Luis A. Shimose; Paola N. Lichtenberger; Lilian M. Abbo; Rupali Jain; Masayuki Nigo; Audrey Wanger; Rafael Araos; Truc T. Tran; Javier Adachi; Robert Rakita; Samuel Shelburne; Robert A. Bonomo; Cesar A. Arias

doi:10.1093/cid/cix014

Multicenter Evaluation of Ceftolozane/Tazobactam for Serious Infections Caused by Carbapenem-Resistant Pseudomonas aeruginosa

Jose M. Munita, Samuel L. Aitken, William R. Miller, Federico Perez, Rossana Rosa, Luis A. Shimose, Paola N. Lichtenberger, Lilian M. Abbo, Rupali Jain, Masayuki Nigo, Audrey Wanger, Rafael Araos, Truc T. Tran, Javier Adachi, Robert Rakita, Samuel Shelburne, Robert A. Bonomo, Cesar A. Arias

Research output: Contribution to journal › Article › peer-review

124 Scopus citations

Abstract

A multicenter, retrospective study of patients infected with carbapenem-resistant Pseudomonas aeruginosa who were treated with ceftolozane/tazobactam was performed. Among 35 patients, pneumonia was the most common indication and treatment was successful in 26 (74%). Treatment failure was observed in all cases where isolates demonstrated ceftolozane-tazobactam minimum inhibitory concentrations ≥8 μg/mL.

Original language	English (US)
Pages (from-to)	158-161
Number of pages	4
Journal	Clinical Infectious Diseases
Volume	65
Issue number	1
DOIs	https://doi.org/10.1093/cid/cix014
State	Published - Jul 1 2017

Keywords

Ceftolozane
P. aeruginosa
carbapenem resistant
multidrug resistant

ASJC Scopus subject areas

Microbiology (medical)
Infectious Diseases

Divisions

Infectious Disease

Access to Document

10.1093/cid/cix014

Cite this

Munita, J. M., Aitken, S. L., Miller, W. R., Perez, F., Rosa, R., Shimose, L. A., Lichtenberger, P. N., Abbo, L. M., Jain, R., Nigo, M., Wanger, A., Araos, R., Tran, T. T., Adachi, J., Rakita, R., Shelburne, S., Bonomo, R. A., & Arias, C. A. (2017). Multicenter Evaluation of Ceftolozane/Tazobactam for Serious Infections Caused by Carbapenem-Resistant Pseudomonas aeruginosa. Clinical Infectious Diseases, 65(1), 158-161. https://doi.org/10.1093/cid/cix014

Munita, JM, Aitken, SL, Miller, WR, Perez, F, Rosa, R, Shimose, LA, Lichtenberger, PN, Abbo, LM, Jain, R, Nigo, M, Wanger, A, Araos, R, Tran, TT, Adachi, J, Rakita, R, Shelburne, S, Bonomo, RA & Arias, CA 2017, 'Multicenter Evaluation of Ceftolozane/Tazobactam for Serious Infections Caused by Carbapenem-Resistant Pseudomonas aeruginosa', Clinical Infectious Diseases, vol. 65, no. 1, pp. 158-161. https://doi.org/10.1093/cid/cix014

@article{24acd77e6b1245a3ac63215569ab9bc6,

title = "Multicenter Evaluation of Ceftolozane/Tazobactam for Serious Infections Caused by Carbapenem-Resistant Pseudomonas aeruginosa",

abstract = "A multicenter, retrospective study of patients infected with carbapenem-resistant Pseudomonas aeruginosa who were treated with ceftolozane/tazobactam was performed. Among 35 patients, pneumonia was the most common indication and treatment was successful in 26 (74\%). Treatment failure was observed in all cases where isolates demonstrated ceftolozane-tazobactam minimum inhibitory concentrations ≥8 μg/mL.",

keywords = "Ceftolozane, P. aeruginosa, carbapenem resistant, multidrug resistant",

author = "Munita, \{Jose M.\} and Aitken, \{Samuel L.\} and Miller, \{William R.\} and Federico Perez and Rossana Rosa and Shimose, \{Luis A.\} and Lichtenberger, \{Paola N.\} and Abbo, \{Lilian M.\} and Rupali Jain and Masayuki Nigo and Audrey Wanger and Rafael Araos and Tran, \{Truc T.\} and Javier Adachi and Robert Rakita and Samuel Shelburne and Bonomo, \{Robert A.\} and Arias, \{Cesar A.\}",

note = "Publisher Copyright: {\textcopyright} 2017 The Author.",

year = "2017",

month = jul,

day = "1",

doi = "10.1093/cid/cix014",

language = "English (US)",

volume = "65",

pages = "158--161",

journal = "Clinical Infectious Diseases",

issn = "1058-4838",

publisher = "Oxford University Press",

number = "1",

}

TY - JOUR

T1 - Multicenter Evaluation of Ceftolozane/Tazobactam for Serious Infections Caused by Carbapenem-Resistant Pseudomonas aeruginosa

AU - Munita, Jose M.

AU - Aitken, Samuel L.

AU - Miller, William R.

AU - Perez, Federico

AU - Rosa, Rossana

AU - Shimose, Luis A.

AU - Lichtenberger, Paola N.

AU - Abbo, Lilian M.

AU - Jain, Rupali

AU - Nigo, Masayuki

AU - Wanger, Audrey

AU - Araos, Rafael

AU - Tran, Truc T.

AU - Adachi, Javier

AU - Rakita, Robert

AU - Shelburne, Samuel

AU - Bonomo, Robert A.

AU - Arias, Cesar A.

PY - 2017/7/1

Y1 - 2017/7/1

N2 - A multicenter, retrospective study of patients infected with carbapenem-resistant Pseudomonas aeruginosa who were treated with ceftolozane/tazobactam was performed. Among 35 patients, pneumonia was the most common indication and treatment was successful in 26 (74%). Treatment failure was observed in all cases where isolates demonstrated ceftolozane-tazobactam minimum inhibitory concentrations ≥8 μg/mL.

AB - A multicenter, retrospective study of patients infected with carbapenem-resistant Pseudomonas aeruginosa who were treated with ceftolozane/tazobactam was performed. Among 35 patients, pneumonia was the most common indication and treatment was successful in 26 (74%). Treatment failure was observed in all cases where isolates demonstrated ceftolozane-tazobactam minimum inhibitory concentrations ≥8 μg/mL.

KW - Ceftolozane

KW - P. aeruginosa

KW - carbapenem resistant

KW - multidrug resistant

UR - https://www.scopus.com/pages/publications/85021792400

UR - https://www.scopus.com/inward/citedby.url?scp=85021792400&partnerID=8YFLogxK

U2 - 10.1093/cid/cix014

DO - 10.1093/cid/cix014

M3 - Article

C2 - 28329350

AN - SCOPUS:85021792400

SN - 1058-4838

VL - 65

SP - 158

EP - 161

JO - Clinical Infectious Diseases

JF - Clinical Infectious Diseases

IS - 1

ER -

Multicenter Evaluation of Ceftolozane/Tazobactam for Serious Infections Caused by Carbapenem-Resistant Pseudomonas aeruginosa

Abstract

Keywords

ASJC Scopus subject areas

Divisions

Access to Document

Other files and links

Fingerprint

Cite this